JP2012046489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012046489A5 JP2012046489A5 JP2011151340A JP2011151340A JP2012046489A5 JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5 JP 2011151340 A JP2011151340 A JP 2011151340A JP 2011151340 A JP2011151340 A JP 2011151340A JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- virus
- use according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 12
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 241000700605 Viruses Species 0.000 claims 8
- 241001466953 Echovirus Species 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 102000006495 integrins Human genes 0.000 claims 4
- 108010044426 integrins Proteins 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002953436A AU2002953436A0 (en) | 2002-12-18 | 2002-12-18 | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| AU2002953436 | 2002-12-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559490A Division JP2006517189A (ja) | 2002-12-18 | 2003-12-18 | 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012046489A JP2012046489A (ja) | 2012-03-08 |
| JP2012046489A5 true JP2012046489A5 (enExample) | 2012-10-11 |
Family
ID=30004521
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559490A Pending JP2006517189A (ja) | 2002-12-18 | 2003-12-18 | 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法 |
| JP2011151340A Pending JP2012046489A (ja) | 2002-12-18 | 2011-07-08 | 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559490A Pending JP2006517189A (ja) | 2002-12-18 | 2003-12-18 | 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7485292B2 (enExample) |
| EP (1) | EP1581257B1 (enExample) |
| JP (2) | JP2006517189A (enExample) |
| KR (1) | KR101171295B1 (enExample) |
| CN (2) | CN102166228B (enExample) |
| AU (1) | AU2002953436A0 (enExample) |
| CA (1) | CA2510227C (enExample) |
| ES (1) | ES2463678T3 (enExample) |
| NZ (1) | NZ541230A (enExample) |
| WO (1) | WO2004054613A1 (enExample) |
| ZA (1) | ZA200505389B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US8236298B2 (en) | 2004-08-20 | 2012-08-07 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
| WO2006074526A1 (en) * | 2005-01-17 | 2006-07-20 | Viralytics Limited | Method and composition for treatment of neoplasms |
| US9566307B2 (en) | 2012-04-19 | 2017-02-14 | Kyushu University, National University Corporation | Pharmaceutical composition |
| ES2566146T3 (es) * | 2013-07-16 | 2016-04-11 | Sia Latima | Virus de ARN oncolítico genéticamente estable, método de fabricación y uso del mismo |
| WO2015080631A1 (en) * | 2013-11-27 | 2015-06-04 | Obschestvo S Ogranichennoy Otvetstvennost`Yu "Panacela Labs" | Improved expression vector for toll-like receptor and agonist and use for treating cancer |
| US20170000832A1 (en) | 2014-02-27 | 2017-01-05 | Viralytics Limited | Combination method for treatment of cancer |
| CN103981152B (zh) * | 2014-04-16 | 2015-01-21 | 武汉博威德生物技术有限公司 | 一种柯萨奇病毒及其制备抗肿瘤药物之应用 |
| AU2017335673B2 (en) | 2016-09-27 | 2024-11-14 | Sator Therapeutics LLC | Optimized oncolytic viruses and uses thereof |
| EP3610870A4 (en) * | 2017-03-31 | 2020-12-09 | Ogata, Hisanobu | METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT |
| CN109419818B (zh) * | 2017-08-24 | 2021-08-10 | 厦门大学 | 一种用于治疗肿瘤的埃可病毒 |
| CN107669707A (zh) * | 2017-11-16 | 2018-02-09 | 邹罡 | 埃可病毒作为溶瘤病毒在抗肿瘤中的应用 |
| MX2021005448A (es) * | 2018-11-13 | 2021-08-11 | Oncorus Inc | Polinucleotidos encapsulados y metodos de uso. |
| US20240299540A1 (en) | 2021-02-05 | 2024-09-12 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113421A (en) * | 1978-02-24 | 1979-09-05 | Fumiaki Taguchi | Large scale cultivation of virus |
| US5585254A (en) | 1987-08-21 | 1996-12-17 | University Of Colorado Foundation, Inc. | Autonomous parvovirus gene delivery vehicles and expression vectors |
| EP0466815A4 (en) | 1989-04-05 | 1992-09-02 | Novacell Corpporation | Infectious targetted replication-defective virion |
| CA2051289C (en) | 1990-09-14 | 2002-11-26 | Robert L. Martuza | Viral mediated destruction of neoplastic cells |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| AU2252092A (en) | 1991-06-24 | 1993-01-25 | Research Foundation Of The State University Of New York, The | De novo cell-free synthesis of picornavirus |
| JPH06509578A (ja) | 1991-07-26 | 1994-10-27 | ユニバーシティ・オブ・ロチェスター | 悪性細胞利用による癌治療法 |
| US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
| SE503225C2 (sv) | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| PT931830E (pt) | 1993-02-16 | 2001-08-30 | Onyx Pharma Inc | Virus citopaticos para terapia e profilaxia de neoplasia |
| PT1486211E (pt) | 1993-04-30 | 2009-02-02 | Wellstat Biologics Corp | Composições para tratamento do cancro utilizando vírus |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
| US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
| US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| CA2323067A1 (en) | 1998-03-12 | 1999-09-16 | The Trustees Of The University Of Pennsylvania | Producer cells for replication selective viruses in the treatment of malignancy |
| US6060316A (en) | 1998-06-09 | 2000-05-09 | President And Fellows Of Harvard College | Methods of targeting of viral entry |
| US6264940B1 (en) | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
| WO2000045853A2 (en) | 1999-02-05 | 2000-08-10 | Arch Development Corporation | Treatment of tumors with genetically engineered herpes virus |
| AU4246900A (en) | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| AU2005201079C1 (en) | 1999-04-15 | 2008-11-06 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| EP1067188A1 (en) | 1999-07-08 | 2001-01-10 | Introgene B.V. | Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR) |
| DE19939095A1 (de) | 1999-08-18 | 2001-02-22 | Univ Eberhard Karls | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer |
| NZ523805A (en) | 1999-09-17 | 2004-09-24 | Pro Virus Inc | Oncolytic virus |
| MXPA02004736A (es) | 1999-11-12 | 2003-01-28 | Oncolytics Biotech Inc | Virus para el tratamiento de trastornos proliferativos celulares. |
| US7001596B1 (en) | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| AU2004202292B2 (en) | 1999-11-25 | 2007-06-14 | Viralytics Limited | Method of Treating a Malignancy in a Subject |
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU770517B2 (en) | 1999-11-25 | 2004-02-26 | Viralytics Limited | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| KR100802403B1 (ko) | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
| CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| AU6814601A (en) | 2000-06-01 | 2001-12-11 | Sloan Kettering Inst Cancer | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| WO2002043647A2 (en) | 2000-12-01 | 2002-06-06 | University Of Ottawa | Oncolytic virus |
| WO2002092132A2 (en) * | 2001-01-05 | 2002-11-21 | Corixa Corporation | Microparticles and methods for delivery of recombinant viral vaccines |
| WO2002087625A1 (en) | 2001-05-02 | 2002-11-07 | Ramot At Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
| EP2140879A1 (en) | 2001-05-09 | 2010-01-06 | M'S Science Corporation | Composition and method for treating cancer using herpes virus |
| DE60239394D1 (de) | 2001-05-11 | 2011-04-21 | Wellstat Biologics Corp | Onkolytische virustherapie |
| CA2352439A1 (en) | 2001-07-17 | 2003-01-17 | Patrick W. K. Lee | Engineering oncolytic viruses |
| JP2004536607A (ja) | 2001-07-23 | 2004-12-09 | オニックス ファーマシューティカルズ，インコーポレイティド | 標的化されたヒト癌細胞において選択的に複製するウイルス変異体 |
| JP2005519091A (ja) | 2002-03-01 | 2005-06-30 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 癌の再発及び転移の予防 |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| WO2003092579A2 (en) | 2002-04-29 | 2003-11-13 | Hadasit Medical Research Services And Development Company Ltd. | Compositions and methods for treating cancer with an oncolytic viral agent |
| MXPA04011007A (es) | 2002-05-09 | 2005-02-14 | Oncolytics Biotech Inc | Metodo para reducir el dolor usando virus oncoliticos. |
| AU2002953436A0 (en) * | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US20050019308A1 (en) | 2003-07-07 | 2005-01-27 | Oncolytics Biotech Inc. | Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac |
| US20070036758A1 (en) | 2003-07-08 | 2007-02-15 | Bertram Jacobs | Mutants of vaccinia virus as oncolytic agents |
| AU2004275832A1 (en) | 2003-09-26 | 2005-04-07 | Novartis Ag | Seneca Valley virus based compositions and methods for treating disease |
| KR20060131975A (ko) | 2004-03-11 | 2006-12-20 | 바이로타르그 피티와이 엘티디 | 변형된 종양 용해 바이러스 |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| US8080240B2 (en) | 2004-10-21 | 2011-12-20 | The Penn State Research Foundation | Parvovirus methods and compositions for killing neoplastic cells |
-
2002
- 2002-12-18 AU AU2002953436A patent/AU2002953436A0/en not_active Abandoned
-
2003
- 2003-12-18 CA CA2510227A patent/CA2510227C/en not_active Expired - Fee Related
- 2003-12-18 EP EP03779569.7A patent/EP1581257B1/en not_active Expired - Lifetime
- 2003-12-18 US US10/539,219 patent/US7485292B2/en not_active Expired - Lifetime
- 2003-12-18 ZA ZA200505389A patent/ZA200505389B/en unknown
- 2003-12-18 JP JP2004559490A patent/JP2006517189A/ja active Pending
- 2003-12-18 KR KR1020057011510A patent/KR101171295B1/ko not_active Expired - Fee Related
- 2003-12-18 NZ NZ541230A patent/NZ541230A/en not_active IP Right Cessation
- 2003-12-18 ES ES03779569.7T patent/ES2463678T3/es not_active Expired - Lifetime
- 2003-12-18 WO PCT/AU2003/001688 patent/WO2004054613A1/en not_active Ceased
- 2003-12-18 CN CN201110091011.1A patent/CN102166228B/zh not_active Expired - Fee Related
- 2003-12-18 CN CN2003801098083A patent/CN1784242B/zh not_active Expired - Fee Related
-
2009
- 2009-02-03 US US12/365,120 patent/US20100062020A1/en not_active Abandoned
-
2011
- 2011-07-08 JP JP2011151340A patent/JP2012046489A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012046489A5 (enExample) | ||
| Marcucci et al. | How to improve exposure of tumor cells to drugs—Promoter drugs increase tumor uptake and penetration of effector drugs | |
| Qian et al. | Berberine reverses breast cancer multidrug resistance based on fluorescence pharmacokinetics in vitro and in vivo | |
| NZ717490A (en) | Methods of treating cancer | |
| Bouche | Compression and entrapment neuropathies | |
| BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
| JP2013155188A5 (enExample) | ||
| JP2014530873A5 (enExample) | ||
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| WO2014145642A3 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
| CO6382135A2 (es) | Terapia especifica y medicamento que usan ligando de integrina para tratar cancer | |
| HK1210699A1 (en) | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy | |
| WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
| JP2018522028A5 (enExample) | ||
| JP2015507020A5 (enExample) | ||
| JP2015044878A5 (enExample) | ||
| UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
| JP2017516842A5 (enExample) | ||
| CN103239464A (zh) | 淫羊藿次苷ii在制备肿瘤化疗药物增敏剂中的用途 | |
| CN102250904B (zh) | 一种预防和/或治疗黑色素瘤的药物 | |
| JP2015529664A5 (enExample) | ||
| Mierzejewska et al. | Novel evidence that hematopoietic stem/progenitor cells (HSPCs) are mobilized during hemolysis in an erythrocyte lysis-derived, sphingosine-1-phosphate (S1P)-dependent manner—the crucial involvement of complement cascade (CC) activation and attenuation of CXCR4 retention signaling | |
| Yurchenko et al. | A138: In vitro oncolytic effects of wild Newcastle disease virus strains and results in vivo virotherapy | |
| CN103202877A (zh) | 丹参总酚酸在制备用于三氧化二砷诱导心脏毒性的保护及协同抗肿瘤作用药物中的应用 | |
| 齐鲁楠 | Vasculogenic mimicry in human hepatocellular carcinoma |